hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06274190, orgStudyIdInfo id: S68746, briefTitle: Personalized Care Pathways for Bowel Symptoms in Rectal Cancer patients_development of E-diary, acronym: Treatable, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-29, primaryCompletionDateStruct date: 2025-10, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: KU Leuven, class: OTHER, collaborators name: Universitaire Ziekenhuizen KU Leuven, descriptionModule briefSummary: Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection, combined with chemoradiotherapy. However, this treatment will negatively impact different aspects of bowel function and the patients' quality of life. These bowel symptoms often remain prevalent, even at 12 months after RC treatment. Most assessment tools are however not capable of capturing the full range or therapeutic-related evolution of these bowel symptoms. Consequently, the aim is to develop a validated bowel diary for diagnosing and evaluation of all bowel symptoms., conditionsModule conditions: Rectal Cancer, conditions: LARS - Low Anterior Resection Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 118, type: ESTIMATED, armsInterventionsModule interventions name: bowel e-diary, outcomesModule primaryOutcomes measure: Selection of items for the newly developed bowel diary, primaryOutcomes measure: Assessment of content validity of the newly developed bowel diary in a post-Delphi patient focus group consisting of 8-12 participants, primaryOutcomes measure: The usability of the newly developed e-diary, assessed with the System Usability Scale (SUS) in patients after rectal surgery for rectal cancer, primaryOutcomes measure: The usability of the newly developed e-diary will be evaluated through conversations with patients who have undergone rectal surgery for rectal cancer, after these patients have used the e-diary for seven consecutive days, primaryOutcomes measure: Construct validity of the newly developed bowel e-diary, primaryOutcomes measure: Criterion validity of the newly developed bowel e-diary, primaryOutcomes measure: Test-retest reliability of the newly developed bowel e-diary, primaryOutcomes measure: Responsiveness of the newly developed bowel e-diary in patients after rectal surgery for rectal cancer. The newly validated e-diary is the primary outcome., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06274177, orgStudyIdInfo id: BTL-785_CTUS1400, briefTitle: Evaluation of the BTL-785F Device for Submental Fat Reduction and Neck Rejuvenation, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-07-26, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: BTL Industries Ltd., class: INDUSTRY, descriptionModule briefSummary: This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment., conditionsModule conditions: Fat Burn, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 37, type: ACTUAL, armsInterventionsModule interventions name: BTL-785-7, outcomesModule primaryOutcomes measure: Submental fat thickness reduction, secondaryOutcomes measure: Incidence of Treatment-related Adverse Events, secondaryOutcomes measure: Change on the Clinician Reported - Submental Fat Rating Scale score, secondaryOutcomes measure: Satisfaction Assessed by the Satisfaction Questionnaire, secondaryOutcomes measure: Change in the submental-cervical angle, secondaryOutcomes measure: Comfort Assessed by Therapy Comfort Questionnaire, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Precision Skin LLC, city: Davie, state: Florida, zip: 33328, country: United States, geoPoint lat: 26.06287, lon: -80.2331, locations facility: Chicago Cosmetic and Dermatologic Research, city: Chicago, state: Illinois, zip: 60654, country: United States, geoPoint lat: 41.85003, lon: -87.65005, locations facility: New Jersey Plastic Surgery (NJPS), city: Montclair, state: New Jersey, zip: 07042, country: United States, geoPoint lat: 40.82593, lon: -74.20903, locations facility: Gentile Facial Plastic and Aesthetic Laser Center, city: Youngstown, state: Ohio, zip: 44512, country: United States, geoPoint lat: 41.09978, lon: -80.64952, hasResults: False
protocolSection identificationModule nctId: NCT06274164, orgStudyIdInfo id: H-54820 / RAI1, briefTitle: Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Baylor College of Medicine, class: OTHER, collaborators name: Doris Duke Charitable Foundation, descriptionModule briefSummary: Currently, there is no clinically available genetic-based treatment for RAI1 (Retinoic Acid-Induced 1) -related disorders other than symptomatic management and there are no established clinical or molecular biomarkers that could be used as measures for the efficacy of therapy in future treatment studies. Biomarkers are measures of what is happening inside the body, shown by the results of laboratory, imaging or other tests.Biomarkers can help doctors and scientists diagnose diseases and health conditions, monitor responses to treatment and see how a person's disease or health condition changes over time.The goal of this observational and laboratory study is to develop clinical, neurophysiology and molecular biomarkers in RAI1-related disorders. The main question\[s\] it aims to answer are:* to characterize the disease features more precisely and analyze the differentiating and overlapping features of RAI1-related disorders (Smith-Magenis syndrome and Potocki-Lupski Syndrome)* to identify clinical, neurophysiology, and laboratory biomarkers that differentiate RAI1-related disorders one from another.Participants will have to complete:* a clinical examination* a blood draw* a skin biopsy (optional)* a sleep studyResearchers will compare patients' blood to control group's blood for biomarker studies., conditionsModule conditions: RAI1 Gene 17P11.2 Deletion+Duplication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Electroencephalography/Polysomnography (EEG/PSG), interventions name: Skin Biopsy, interventions name: Blood draw, outcomesModule primaryOutcomes measure: Rate of neurological clinical finding, primaryOutcomes measure: Rate of electroencephalogram (EEG) and/or sleep abnormalities, primaryOutcomes measure: Concentration of downstream molecular pathway interactors of RAI1, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Texas Children's Hospital, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Davut Pehlivan, MD, role: CONTACT, phone: 713-798-6970, email: pehlivan@bcm.edu, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06274151, orgStudyIdInfo id: H-22038917, briefTitle: Optimal Treatment of Acute Skeletal Muscle Injury, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Bispebjerg Hospital, class: OTHER, descriptionModule briefSummary: Acute muscle strain injuries occur both during sports, in leisure time activities and during manual occupation and represent a major clinical challenge and has societal economic costs. The recovery time is long and a substantial injury recurrence is observed. Despite current best evidence rehabilitation with early mechanical loading, a significant loss of muscle mass, fatty infiltration and formation of scar tissue is reported.Animal models and human in vitro experiments suggest that inflammation is vital in the early period after an injury, however an inhibition of inflammatory processes is beneficial for healing.We investigate here whether a pharmacological inhibition of inflammatory pathways in the 2nd week following a muscle strain injury will provide a better clinical outcome and an advantageous cellular profile than rehabilitative training alone would., conditionsModule conditions: Muscle Strain, Multiple Sites, conditions: Inflammation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Naproxen 500 Mg, interventions name: Rehabilitation, interventions name: Placebo, outcomesModule primaryOutcomes measure: Effect of anti-inflammatory medicine on cellular profile in skeletal muscle, secondaryOutcomes measure: Functional outcome performance, secondaryOutcomes measure: Functional outcome re-injury rate, secondaryOutcomes measure: Functional outcome Patient Related Outcome Measures (PROM), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06274125, orgStudyIdInfo id: AslıDemircioglu1, briefTitle: Evaluation of Kidney Damage Using NGAL Measurements, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: The main objective of this study is to evaluate whether blood NGAL measurement provides superiority over sCr and BUN tests in early diagnosis for assessing renal function in patients undergoing robotic urological surgery., conditionsModule conditions: Prostatectomy, conditions: Neutrophil Gelatinase-Associated Lipocalin, conditions: Kidney Function Tests, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 55, type: ESTIMATED, armsInterventionsModule interventions name: Robotic-Assisted Laparoscopic Radical Prostatectomy, outcomesModule primaryOutcomes measure: The main objective of this study is to evaluate whether blood NGAL measurement has superiority over sCr and BUN tests in terms of early diagnosis for assessing kidney function in patients undergoing robotic urologic surgery., secondaryOutcomes measure: The relationship between demographic parameters such as age, BMI, comorbidities, and ASA classification will be evaluated in relation to the development of AKI., secondaryOutcomes measure: The evaluation of the relationship between intraabdominal pressure and the development of AKI., secondaryOutcomes measure: The relationship between intraoperative mean arterial pressure (MAP) and NGAL (Neutrophil Gelatinase-Associated Lipocalin) values., eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara Bilkent City Hospital, status: RECRUITING, city: Ankara, state: Çankaya, zip: 06530, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06274112, orgStudyIdInfo id: 1K23MH135222, briefTitle: Using TMS to Understand Neural Processes of Social Motivation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2029-09, completionDateStruct date: 2029-09, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Auburn University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to use transcranial magnetic stimulation (TMS) to better understand the neural circuits associated with social motivation.Participant includes four study visits each that range from 1.5 - 3.0 hours in duration over approximately a one month period. The first study visit involves answering survey questions, a clinical interview, and computer tasks. The second study visit involves a magnetic resonance imaging (MRI) scan, computer tasks, and a brief TMS protocol. The second and third study visits involve a full session of TMS followed by an MRI scan and computer tasks.Adults in the Auburn/Apelika area who avoid social situations, experience symptoms of depression or social anxiety, and are between 25 years old and 50 years old are eligible to participate., conditionsModule conditions: Social Avoidant Behavior, conditions: Major Depressive Disorder, conditions: Social Anxiety Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: All participants will receive each dose of TMS in a counterbalanced order (AB or BA), primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: TMS, outcomesModule primaryOutcomes measure: Social motivation, primaryOutcomes measure: Neural circuit function, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 50 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06274086, orgStudyIdInfo id: S2022-2027-0001, briefTitle: Two-session Catheter-directed Sclerotherapy Using Ethanol for Endometrioma, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-06-01, primaryCompletionDateStruct date: 2023-03-31, completionDateStruct date: 2023-03-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Asan Medical Center, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the safety and clinical outcomes of two-session catheter-directed sclerotherapy (CDS) with 96% ethanol in patients with endometrioma. The main question it aims to answer is:• Is two-session CDS with 96% ethanol safe and effective for treating endometrioma?Participants will:* Receive the first session CDS for endometrioma* Carry the catheter overnight and be monitored in the patient ward* Receive the second session CDS the next day, conditionsModule conditions: Sclerotherapy, conditions: Endometrioma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 22, type: ACTUAL, armsInterventionsModule interventions name: Two-session catheter-directed sclerotherapy, outcomesModule primaryOutcomes measure: Recurrence, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Asan Medical Center, city: Seoul, zip: 05505, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06274073, orgStudyIdInfo id: E2-22-2566, briefTitle: Double-dorsal Versus Single-volar Digital Block, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-10-12, primaryCompletionDateStruct date: 2023-07-12, completionDateStruct date: 2023-09-12, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: The aim of this study is to compare the traditional dorsal double injection digital block with the palmar single injection technique in the suturing of acute traumatic hand finger lacerations in terms of injection pain score (NRS), anesthesia onset time, and success of anesthesia.It is understood that single injection digital block and double injection digital block techniques do not have significant advantages over each other in terms of pain levels and procedure times.However, the need for rescue anesthesia was evaluated to be lower in the single injection digital block technique. This difference is especially due to measurements in the volar region incisions.According to the results of this study, we think that choosing the single injection digital block technique for volar region incisions is a more rational approach, especially in terms of the data of the need for rescue anesthesia., conditionsModule conditions: Laceration of Skin, conditions: Anesthesia, Local, conditions: Pain, conditions: Nerve Block, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two parallel groups (two digital block techniques), primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 160, type: ACTUAL, armsInterventionsModule interventions name: Dorsal digital block, interventions name: Palmar digital block, outcomesModule primaryOutcomes measure: Anesthesia pain score, secondaryOutcomes measure: Anesthesia onset time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara City Hospital Emergency Medicine Department, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06274047, orgStudyIdInfo id: 2023-0409, secondaryIdInfos id: NCI-2024-01553, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-31, primaryCompletionDateStruct date: 2027-06-30, completionDateStruct date: 2029-06-30, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, collaborators name: Janssen Scientific Affairs, LLC, descriptionModule briefSummary: 1. Personalize treatment for prostate cancer based on how aggressive the disease is and2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy., conditionsModule conditions: Androgen Axis Suppression, conditions: Prostatectomy, conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Apalutamide, interventions name: Androgen Deprivation Therapy, outcomesModule primaryOutcomes measure: Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue), eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Karen Hoffman, MD, role: CONTACT, phone: 713-563-2339, email: khoffman1@mdanderson.org, contacts name: Karen Hoffman, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06274034, orgStudyIdInfo id: 23-006870, secondaryIdInfos id: NCI-2024-01019, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 23-006870, type: OTHER, domain: Mayo Clinic Institutional Review Board, briefTitle: MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-08, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This early phase I trial evaluates the feasibility and impact of a meditation headband system (MUSE-S) for breast cancer survivors. Anxiety and insomnia are among the most common distresses in breast cancer survivors during and after chemotherapy, in part due to the side effects of chemotherapy, fear of cancer coming back, progression of the cancer, and uncertainty of the future. These distresses impair patients' well-being and quality of life (QOL) in general, and their cancer treatment adherence and effectiveness in particular. Meditation has been demonstrated to be an effective management tool of stress and anxiety and is given the highest level of evidence (grade A) in the systematic review-based guidelines by the Society of Integrative Medicine. The portable, interactive, electroencephalographic (EEG) Muse headband guided meditation has been shown to improve fatigue, QOL, and stress in newly diagnosed breast cancer patients. The MUSE-S Headband System may decrease anxiety and insomnia among breast cancer survivors., conditionsModule conditions: Breast Carcinoma, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Electronic Health Record Review, interventions name: Medical Device Usage and Evaluation, interventions name: Meditation Therapy, interventions name: Survey Administration, outcomesModule primaryOutcomes measure: Frequency of use of meditation, primaryOutcomes measure: Feasibility of a wearable electroencephalographic (EEG) headband (Muse™ S Headband), primaryOutcomes measure: Impact of interactive meditation and sleep support through the Muse-S™ system, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Stacy D. D'Andre, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False